Session » Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1215

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1227

A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout

9:00AM-11:00AM: Abstract Number: 1240

A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study

9:00AM-11:00AM: Abstract Number: 1224

AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile

9:00AM-11:00AM: Abstract Number: 1229

AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial

9:00AM-11:00AM: Abstract Number: 1230

Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank

9:00AM-11:00AM: Abstract Number: 1223

Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1220

How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1233

Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout

9:00AM-11:00AM: Abstract Number: 1221

Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab

9:00AM-11:00AM: Abstract Number: 1231

Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase

9:00AM-11:00AM: Abstract Number: 1234

Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?

9:00AM-11:00AM: Abstract Number: 1225

Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound

9:00AM-11:00AM: Abstract Number: 1238

Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter

9:00AM-11:00AM: Abstract Number: 1218

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients

9:00AM-11:00AM: Abstract Number: 1235

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients

9:00AM-11:00AM: Abstract Number: 1226

Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity

9:00AM-11:00AM: Abstract Number: 1217

Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development

9:00AM-11:00AM: Abstract Number: 1216

Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare

9:00AM-11:00AM: Abstract Number: 1222

Relationships Between Allopurinol Dose, Oxypurinol Levels and Serum Urate – in Search of an Oxypurinol Therapeutic Concentration

9:00AM-11:00AM: Abstract Number: 1228

Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout

9:00AM-11:00AM: Abstract Number: 1236

Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1239

The Association Between Urate and CSF Markers of Alzheimer’s Disease in a Population-Based Sample of 70-Year-Olds

9:00AM-11:00AM: Abstract Number: 1214

The Effects of Pegloticase on Mean Arterial Blood Pressure: An Age Modulated Relationship?

9:00AM-11:00AM: Abstract Number: 1237

Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans

9:00AM-11:00AM: Abstract Number: 1219

Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population

9:00AM-11:00AM: Abstract Number: 1232

Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].